<DOC>
	<DOCNO>NCT01658332</DOCNO>
	<brief_summary>TITLE : Circulating tumor cell identification advance stage non-small cell lung cancer ( CIRCUBRONCH ) BACKGROUND : Circulating tumor cell identification new field research oncology , study conduct success breast prostate cancer . Nearly 80 % lung cancer diagnose advanced stage ( IIIB , IV ) . Circulating tumor cell identification monitor cell treatment could help clinician detect relapse prognostic factor . PRIMARY OBJECTIVE : Circulating tumor cell identification , monitoring advanced stage lung cancer ( IIIB IV ) . SECONDARY OBJECTIVES : Predictive value monitor circulate tumor cell therapeutic response . Prognostic value identification circulate tumor cell time diagnosis . STUDY DESIGN : This study prospective , monocentrique trial analyze identification circulate tumor cell stage IIIB , IV non-small cell lung cancer . Duration inclusion : 54 month . Duration study : 66 month . PROCEDURES : Detection circulate tumor cell CellSearch system ( Veridex ) , cut-off 5 cells/7,5 ml blood . SAMPLE SIZE : 200 patient STATISTICAL ANALYSIS : Detection circulate tumor cell predict 20 % stage IIIB , IV non-small cell lung cancer include study . The cut-off 5 circulate tumor cell per 7,5 ml blood .</brief_summary>
	<brief_title>Circulating Tumor Cells Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<criteria>Advanced stage NSCLC ( stage IIIB , IV ) measurable evaluable disease diagnosis . Age â‰¥ 18 year . Measurable evaluable disease accord RECIST criterion . Ability sign inform consent . Prior cancer within 5 year , except nonmelanoma skin cancer , situ cervical cancer . Prior chemotherapy , radiation surgery lung cancer . Inability comply study and/or followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>circulate tumor cell</keyword>
	<keyword>prospective</keyword>
	<keyword>monocentrique trial</keyword>
</DOC>